Chicago, Illinois 60611

  • Small Intestine Cancer


RATIONALE: The use of endoscopy to place metal stents in the duodenum is less invasive than surgery for treating cancer-related duodenal obstruction and may have fewer side effects and improve recovery. PURPOSE: Phase I/II trial to study the effectiveness of endoscopic placement of metal stents in treating patients who have cancer-related obstruction of the duodenum.

Study summary:

OBJECTIVES: - Determine the objective response and clinical outcome in patients with duodenal obstruction secondary to malignancy treated with enteral Wallstents. - Evaluate the efficacy and safety of this treatment in these patients. - Evaluate the quality of life of these patients after enteral Wallstent placement. OUTLINE: Patients undergo enteral Wallstent placement through an endoscope under fluoroscopic guidance into the duodenum. Quality of life is assessed at 48 hours and 6 months after procedure. Patients are followed at 48 hours, 30 days, 6 months, and then yearly thereafter until death. PROJECTED ACCRUAL: A total of 20 patients will be accrued for this study.


DISEASE CHARACTERISTICS: - Endoscopically confirmed localized tumor as the cause of duodenal obstruction - All primary tumor types are eligible - No prior duodenal Wallstents - Must have symptoms of gastrointestinal obstruction, including: - Inability to move bowels, absence of flatus, nausea/vomiting, abdominal pain, or diarrhea PATIENT CHARACTERISTICS: Age: - 18 and over Performance status: - ECOG 0-3 Life expectancy: - Not specified Hematopoietic: - Platelet count greater than 50,000/mm^3 Hepatic: - INR no greater than 1.5 times upper limit of normal Renal: - Not specified Cardiovascular: - No cardiac condition Other: - Not pregnant or nursing - Fertile patients must use effective contraception - No significant active infection (e.g., pneumonia, peritonitis, or wound abscess) that would preclude endoscopy - No other serious concurrent illness - No uncontrolled metabolic disease (e.g., diabetes mellitus or hypothyroidism) - No dementia, psychiatric disorder, or altered mental status that would preclude compliance - History of other neoplastic disease allowed - Veterans Administration patients are not eligible PRIOR CONCURRENT THERAPY: Biologic therapy: - Not specified Chemotherapy: - Prior or concurrent chemotherapy allowed Endocrine therapy: - Not specified Radiotherapy: - Prior or concurrent radiotherapy allowed Surgery: - At least 3 weeks since prior surgery and recovered



Primary Contact:

Study Chair
Willis G. Parsons, MD, PC
Robert H. Lurie Cancer Center

Backup Contact:


Location Contact:

Chicago, Illinois 60611
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source:

Date Processed: June 23, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on The form below is not enabled.